GlassScriptPhysician profile
Thomas L Lane
NPI 1295053320
$11,472.98
in general payments reported to CMS, 2019-2025
30 companies · $353 in 2025
The $353 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $614 · 2020: $213 · 2021: $368 · 2022: $243 · 2023: $9,221 · 2024: $461 · 2025: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,500 · Food and Beverage: $1,788 · Travel and Lodging: $747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,500.00 |
| Food and Beverage | $1,788.25 |
| Travel and Lodging | $746.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,550.10 | 2023-2024 | Davinci Xi, Da Vinci Surgical System |
| Abbvie INC. | $875.62 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $414.03 | 2023-2025 | Myfembree |
| Hologic Sales and Service, LLC | $302.56 | 2019-2025 | Myosure Tissue Removal Device, Fluent Fluid Management System, Omni Hysteroscope |
| Pfizer INC. | $268.94 | 2019-2025 | |
| Organon LLC | $108.28 | 2023-2025 | Nexplanon |
| Amag Pharmaceuticals, INC. | $107.85 | 2019-2020 | |
| Astellas Pharma US INC | $101.69 | 2023-2024 | Veozah |
| Millicent US INC | $71.24 | 2020-2025 | Intrarosa, Femring |
| Myovant Sciences INC. | $59.19 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.15 | 2019-2023 | |
| Duchesnay USA Incorporated | $51.46 | 2019 | |
| Innovation Technologies INC | $50.02 | 2023-2025 | Irrisept |
| Lupin INC. | $41.50 | 2019 | |
| Roche Diagnostics Corporation | $39.14 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $36.97 | 2019-2021 | |
| Minerva Surgical, INC | $35.91 | 2023 | |
| Sage Therapeutics, LLC | $34.76 | 2020-2022 | |
| Exeltis, USA INC. | $33.02 | 2019 | |
| Exact Sciences Corporation | $30.16 | 2023 | Cologuard Collection Kit |
| Alexion Pharmaceuticals, INC. | $30.05 | 2024 | Ultomiris |
| Coopersurgical, INC. | $29.80 | 2025 | Paragard T 380a |
| Currax Pharmaceuticals LLC | $29.26 | 2022 | |
| Daiichi Sankyo INC. | $22.44 | 2025 | Injectafer |
| Boston Scientific Corporation | $18.46 | 2025 | Bulkamid |
| Medtronic, INC. | $17.40 | 2023 | Truclear |
| Therapeuticsmd, INC. | $15.79 | 2022 | |
| Becton, Dickinson and Company | $15.67 | 2023 | Bd Onclarity |
| Avion Pharmaceuticals | $14.81 | 2019 | |
| Allergan, INC. | $13.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Lane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.